Corrigendum to “Outcomes of patients with refractory upper GI cancers enrolled in phase I trials: a 10-year analysis from the Sarah Cannon Research Institute UK Drug Development Unit”

Author unknown

Open source

DOI
10.1177/17588359251334877
Published
2025-01
Container
Therapeutic Advances in Medical Oncology
Publisher
SAGE Publications
Open access
unknown

Credibility signals

uncertain Score 58/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1177/17588359251334877,
  title = {Corrigendum to “Outcomes of patients with refractory upper GI cancers enrolled in phase I trials: a 10-year analysis from the Sarah Cannon Research Institute UK Drug Development Unit”},
  year = {2025},
  journal = {Therapeutic Advances in Medical Oncology},
  doi = {10.1177/17588359251334877},
  url = {https://doi.org/10.1177/17588359251334877}
}

RIS

TY  - JOUR
TI  - Corrigendum to “Outcomes of patients with refractory upper GI cancers enrolled in phase I trials: a 10-year analysis from the Sarah Cannon Research Institute UK Drug Development Unit”
PY  - 2025
JO  - Therapeutic Advances in Medical Oncology
DO  - 10.1177/17588359251334877
UR  - https://doi.org/10.1177/17588359251334877
ER  - 

APA

Corrigendum to “Outcomes of patients with refractory upper GI cancers enrolled in phase I trials: a 10-year analysis from the Sarah Cannon Research Institute UK Drug Development Unit”. (2025). Therapeutic Advances in Medical Oncology. https://doi.org/10.1177/17588359251334877

Source records